Um alle Funktionen dieser Seite zu nutzen, aktivieren Sie bitte die Cookies in Ihrem Browser.
my.bionity.com
Mit einem my.bionity.com-Account haben Sie immer alles im Überblick - und können sich Ihre eigene Website und Ihren individuellen Newsletter konfigurieren.
- Meine Merkliste
- Meine gespeicherte Suche
- Meine gespeicherten Themen
- Meine Newsletter
3.269 Aktuelle Fachpublikationen von AACR Publications
rss![]() |
Sie können Ihre Recherche weiter verfeinern. Wählen Sie aus dem linken Bereich passende Suchfilter aus, um Ihre Ergebnisse gezielt einzugrenzen. |
15.05.2017 | American Association for Cancer Research, Cancer Research, 2017
Gholamin and colleagues treated malignant pediatric brain tumor models with a humanized anti-CD47 antibody (Hu59-G4). In primary and metastatic high-risk medulloblastoma, Hu5F9-G4 inhibited growth in vivo , including CD15-positive putative medulloblastoma stem cells. Because children with group 3
15.05.2017 | Jonathan Rios-Doria; Jay Harper; Raymond Rothstein; Leslie Wetzel; Jon Chesebrough; Allison Marrero; Cui Chen; Patri ..., Cancer Research, 2017
Immunogenic cell death (ICD) is the process by which certain cytotoxic drugs induce apoptosis of tumor cells in a manner that stimulates the immune system. In this study, we investigated whether antibody–drug conjugates (ADCS) conjugated with pyrrolobenzodiazepine dimer (PBD) or tubulysin ...
15.05.2017 | American Association for Cancer Research, Cancer Research, 2017
In this article [(Cancer Res 2016;76:5756–67)][1], which appeared in the October 1, 2016, issue of Cancer Research ([1][2]), there are errors in Figs. 2A and 6E. The authors used one trimmed image/blot to fit the size of the others. In these two panels, they accidentally kept the “ruler image/
15.05.2017 | Ruth J. Davis; Ellen C. Moore; Paul E. Clavijo; Jay Friedman; Harrison Cash; Zhong Chen; Chris Silvin; Carter Van Wa ..., Cancer Research, 2017
Checkpoint inhibitors are relatively inefficacious in head and neck cancers, despite an abundance of genetic alterations and a T-cell–inflamed phenotype. One significant barrier to efficacy may be the recruitment of myeloid-derived suppressor cells (MDSC) into the tumor microenvironment. Here we ...
15.05.2017 | Claudia Galuschka; Rumyana Proynova; Benjamin Roth; Hellmut G. Augustin; Karin Müller-Decker, Cancer Research, 2017
The devastating diseases of human cancer are mimicked in basic and translational cancer research by a steadily increasing number of tumor models, a situation requiring a platform with standardized reports to share model data. Models in Translational Oncology (MiTO) database was developed as a ...
15.05.2017 | Min Fang; Yongkui Li; Kai Huang; Shanshan Qi; Jian Zhang; Witold Zgodzinski; Marek Majewski; Grzegorz Wallner; Stani ..., Cancer Research, 2017
The expression and biological role of IL33 in colon cancer is poorly understood. In this study, we show that IL33 is expressed by vascular endothelial cells and tumor cells in the human colon cancer microenvironment. Administration of human IL33 and overexpression of murine IL33 enhanced human ...
15.05.2017 | Sarah Tomkovich; Ye Yang; Kathryn Winglee; Josee Gauthier; Marcus Mühlbauer; Xiaolun Sun; Mansour Mohamadzadeh; Xiul ..., Cancer Research, 2017
Inflammation and microbiota are critical components of intestinal tumorigenesis. To dissect how the microbiota contributes to tumor distribution, we generated germ-free (GF) ApcMin/+ and ApcMin/+ ; Il10−/− mice and exposed them to specific-pathogen-free (SPF) or colorectal cancer-associated ...
15.05.2017 | American Association for Cancer Research, Cancer Research, 2017
In this article [(Cancer Res 2016;76:6964–74)][1], which was published in the December 1, 2016, issue of Cancer Research ([1][2]), the authors regret that the legend for Supplementary Fig. S3 incorrectly noted “[…]as in panels for Fig. 2B and C.” It should read, “[…]as in panels for Fig
15.05.2017 | Sharon Seiko Hori; Amelie M. Lutz; Ramasamy Paulmurugan; Sanjiv Sam Gambhir, Cancer Research, 2017
An effective cancer blood biomarker screening strategy must distinguish aggressive from nonaggressive tumors at an early, intervenable time. However, for blood-based strategies to be useful, the quantity of biomarker shed into the blood and its relationship to tumor growth or progression must be ...
15.05.2017 | Mikolaj Medon; Eva Vidacs; Stephin J Vervoort; Jason Li; Misty R. Jenkins; Kelly M. Ramsbottom; Joseph A. Trapani; M ..., Cancer Research, 2017
Histone deacetylase inhibitors (HDACi) may engage host immunity as one basis for their antitumor effects. Herein, we demonstrate an application of this concept using the HDACi panobinostat to augment the antitumor efficacy of trastuzumab (anti-HER2) therapy, through both tumor cell autonomous and ...
Sie erhalten passend zu Ihrer Suche die neusten Suchergebnisse per E-Mail. Dieser Service ist für Sie kostenlos und kann jederzeit abbestellt werden.